newsfilter
← Latest News
GlobeNewswire·

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

– Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR